1[1]Reyher UV,Starter J,Kittstein W,et al.Colon carcinoma cells as different mechanisms to escape CD95-mediated apoptosis[J].Cancer Res,1998,58:526-534.
2[2]Ungefroren H,Voss M,Jansen M,et al.Human pancreatic adenocarcinomas express Fas and FasL yet are resistant to Fas-mediated apoptosis[J].Cancer Res,1998,58:1741-49.
3[3]Hahne M,Rimoldi D,Schroter M,et al.Melanoma cell expression of Fas(Apo1/CD95)ligand:implications of tumor immune escape[J].Science,1996,274(5291):1363-66.
4[4]O'Connell J,O'Sullivan GC,Collins JE,et al.The Fas counterattack:Fas-mediated T cell killing by colon cancer cells expressing Fas ligand[J].J Exp Med,1996,184(3):1075-82.
5[5]Butter LM,Hewett PJ,Butler WJ,et al.Down regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement.Br J Cancer,1998,77(9):1454-59.
6[6]Jodo S,Kobayashi S,Nakajima Y,et al.Elevated serum levels of soluble Fas/Apo-1(CD95) in patients with hepatocellular cancer.Clin Exp Immunol,1998,112(2):166-171.
8[8]Mizutani Y,Yoshiola O,Banavida B.Prognostic significance of soluble Fas in the serum of patients with bladder cancer.J Urol,1998,160(2);571-6.
9[9]Gratas C, Tohma Y,Barnas C,et al.Up-regulation of Fas ligand and Down-regulation of Fas expression in human esophageal cancer.Cancer Res,1998,58(10):2057-62.
10[10]Lee SH,Shin MS,Park WS,et al.Alterations of Fas(Apo-1/CD95) gene in non-small cell lung cancer.Oncogene,1999,18(25):3754-60.
